Skip to content
OpenDue June 4, 2026

Notice of Intent: LUTATHERA� (lutetium Lu 177 dotatate) and PLUVICTO� (lutetium Lu 177 vipivotide tetraxetan)

DEPT OF DEFENSE

Who can apply

No Set aside used. NONE

About this opportunity

The Defense Health Agency (DHA), Healthcare Contracting Division � Northeast (HCD-NE), Department of Radiology at Walter Reed National Military Medical Center (WRNMMC), intends to award a firm fixed price contract on a sole source basis to Novartis Pharmaceuticals Corporation (Cage: 04520). The anticipated award will be made under the statutory authority permitting Other than Full and Open Competition pursuant to FAR 6.302-1 �Only one responsible source and no other supplies or services will satisfy agency requirements�. The contract is intended to procure LUTATHERA� (lutetium Lu 177 dotatate) and PLUVICTO� (lutetium Lu 177 vipivotide tetraxetan) exclusively developed, manufactured, and supplied by Novartis Pharmaceuticals Corporation (Cage: 04520). This notice of intent is NOT a request f...

Finding similar opportunities...